Martín GT, González JB, Martínez GS, Gutiérrez CV

Language: Spanish
References: 26
Page: 79-84
PDF size: 247.30 Kb.

ABSTRACT

In the last few years many drugs which inhibit the epidermal growth factor receptor are being used in the treatment of solid tumors. These drugs are usually well tolerated, and cutaneous eruptions are the most frequent adverse effect associated with their use, especially acneiform eruptions.
We present eight cases of acneiform eruptions associated with the use of epidermal growth factor receptor inhibitors showing their clinical features, the findings of the bacteriological and mycological cultures, their prognostic implications, management and response to treatment.

REFERENCES

1. Jacot W, Bessis D, Jorda E et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patiens with solid tumours. Br J Dermatol 2004;151:238-41.

2. Van Doorn R, Kirtsching G, Scheffer E et al. Follicular and epidermal alterations in atiens treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147:598-601.

3. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patiens treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76.

4. Plewig G, Kligman AM. Acne and rosacea. 3rd edition. Berlin: Springer-Verlag 2000.

5. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marked of treatment outcome? Oncology (Huntingt) 2003;17:23-8.

6. Martínez De Lagrán Z, Ratón JA, Lasa O, Acebo E y Díaz-Pérez JL. Erupción acneiforme por inhibidores del receptor de crecimiento epidérmico. Actas Dermosifiliográficas 2005;96:450-4.

7. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.

8. Walon L, Gilbeau C, Lachapelle JM. Eruptions acneiformes induites par le cétuximab. Ann Dermatol Venereol 2003;130:443-6.

9. Nedle MN. Safety experience with IMCC255, an antiepidermal growth factor receptor antibody. Semin Oncol 2002;29:55-60.

10. Alvarez-Ruiz SB, Dauden E. Efectos dermatológicos de gefitinib (Iressa) un nuevo agente contra el cáncer. Dermatol Pract 2004;12:10-3.

11. Herbst RS, LoRusso PM, Purdom M, Ward D : Dermatologic side effects associated with gefi tinib therapy: Clinical experience and management. Clin Lung Cancer 2003;4:366-9.

12. Cortesi E, De Pasquale Ceratti A, Dauria G, Nelli F, Evangelista ML, Mazzoli M, Di Fonzo C, Pizzardi N, Picone V, Lugini A. Management of cutaneous adverse effects during treatment with ZD1839 in advanced nonsmall cell lung cancer (NSCLC): Surprising efficacy of early local treatment. Proc Am Soc Clin Oncol 2004;22:Abstract 7100.

13. Purdom M. Management of acneiform rashes related to gefitinib therapy. Clin J Oncol Nurs 2004;8:316-7.

14. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Benporat L, Sachs DL, Heelan RT, Miller VA. Practical manegement of patiens with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-74.

15. Treudler R, Zouboulis CC. Follicular drug erupción induced by gefitinib (ZD 1839, Iressa): Clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures. Dermatology 2005;21:375-6.

16. Isarría MJ, Alonso I, Segurado A, Ortiz J, Vanaclocha F. Reacción cutánea secundaria al tratamiento con Iressa (ZD 1839). Actas Dermosifiliográficas 2004;95:459-61.

17. Fernández-Galar M, Espana A, López-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004;29:138-40.

18. Yang TS, Chen KJ, Yin MC, Wang RC, Lin YC. Paronychia and skin hiperpigmentation induced by gefitinib in advanced nonsamm-cell lung cancer. J Clin Oncol 2004;22:4646-8.

19. Pascual JC, Bañuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD 1839). Br J Dermatol 2004;151:111-2.

20. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KJ. Epidermal growth factor receptor inhibition induces trichomegalia. Acta Oncol 2003;42:345-6.

21. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leadind to enhanced skin inflammation. Am J Pathol 2003;163:303-12.

22. Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 1985;85:239-45.

23. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patiens: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.

24. Philpott MP, Kealey T. Effects of ECF on the morphology and patterns of DNA synthesis in isolated human hair follicles. J Invest Dermatol 1994.

25. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patiens treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-6.

26. Micantonio T, Concetta M, Ricevuto E, Ficorella C, Marcheti P, Peris K. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to Cetuximab therapy. Arch Dermatol 2005;141.